Literature DB >> 9667368

Soluble tumor necrosis factor-alpha (TNF-alpha) receptors in human colostrum and milk bind to TNF-alpha and neutralize TNF-alpha bioactivity.

E S Buescher1, P McWilliams-Koeppen.   

Abstract

We used column chromatography, affinity binding, and bioassay methods to address whether the soluble tumor necrosis factor (TNF)-alpha receptors present in human colostrum and milk bind to and modify TNF-alpha bioactivity. In gel chromatography experiments, soluble TNF-alpha receptor I (sTNFRI) and sTNFRII in human colostrum sequentially increased their molecular sizes from 49 kD to 71 kD and 60 kD, respectively, after addition of increasing molar excesses of recombinant TNF-alpha. Application of colostrum to a TNF-alpha affinity matrix followed by washing and elution resulted in 2925-fold enrichment of sTNFRI, consistent with sTNFRI binding to the TNF-alpha affinity matrix. In other samples of colostrum and milk, the content of both sTNFRI and sTNFRII decreased significantly after passage over the matrix, but the material eluted from the matrix lost the ability to rebind to the TNF-alpha and was not active in a WEHI-13var bioassay for TNF-alpha. Specimens of human colostrum and milk diluted 1:16 shifted the LD50 for TNF-alpha 4-fold in this bioassay, and milk protection of WEHI-13var cells against TNF-alpha was significantly diminished after passage down the TNF-alpha affinity matrix (p < 0.001). Affinity purification of milk sTNFRI using polyclonal anti-sTNFRI produced fractions containing proteins of 30 kD, which could be visualized by Western blot using polyclonal anti-sTNFRI. Addition of this fraction to the WEHI-13var bioassay reversed the effects of 10 pg/mL TNF-alpha in the assay. These data demonstrate that sTNFRI and II from human colostrum and milk bind to TNF-alpha, that both colostrum and milk interfere with the bioactivity of TNF-alpha, and that affinity-purified sTNFRI from human milk blocks the bioactivity of TNF-alpha. These effects may contribute to the anti-inflammatory character of human colostrum and milk.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9667368     DOI: 10.1203/00006450-199807000-00006

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  9 in total

1.  Oral administration of immunoglobulin G-enhanced colostrum alleviates insulin resistance and liver injury and is associated with alterations in natural killer T cells.

Authors:  T Adar; A Ben Ya'acov; G Lalazar; Y Lichtenstein; D Nahman; M Mizrahi; V Wong; B Muller; G Rawlin; Y Ilan
Journal:  Clin Exp Immunol       Date:  2012-02       Impact factor: 4.330

Review 2.  Oropharyngeal administration of colostrum to extremely low birth weight infants: theoretical perspectives.

Authors:  N A Rodriguez; P P Meier; M W Groer; J M Zeller
Journal:  J Perinatol       Date:  2008-09-04       Impact factor: 2.521

3.  Evolution of the mammary gland defense system and the ontogeny of the immune system.

Authors:  Armond S Goldman
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-07       Impact factor: 2.673

Review 4.  Growth hormone and prolactin--molecular and functional evolution.

Authors:  Isabel A Forsyth; Michael Wallis
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-07       Impact factor: 2.673

5.  Differential gender response to respiratory infections and to the protective effect of breast milk in preterm infants.

Authors:  M Inés Klein; Eduardo Bergel; Luz Gibbons; Silvina Coviello; Gabriela Bauer; Alicia Benitez; M Elina Serra; M Florencia Delgado; Guillermina A Melendi; Susana Rodríguez; Steven R Kleeberger; Fernando P Polack
Journal:  Pediatrics       Date:  2008-06       Impact factor: 7.124

Review 6.  Human milk composition: nutrients and bioactive factors.

Authors:  Olivia Ballard; Ardythe L Morrow
Journal:  Pediatr Clin North Am       Date:  2013-02       Impact factor: 3.278

7.  Alleviation of insulin resistance and liver damage by oral administration of Imm124-E is mediated by increased Tregs and associated with increased serum GLP-1 and adiponectin: results of a phase I/II clinical trial in NASH.

Authors:  Meir Mizrahi; Yehudit Shabat; Ami Ben Ya'acov; Gadi Lalazar; Tomer Adar; Victor Wong; Brian Muller; Grant Rawlin; Yaron Ilan
Journal:  J Inflamm Res       Date:  2012-12-20

8.  Lactaptin is a human milk protein inducing apoptosis of MCF-7 adenocarcinoma cells.

Authors:  V V Nekipelaya; D V Semenov; M O Potapenko; E V Kuligina; Y u Y a Kit; I V Romanova; V A Richter
Journal:  Dokl Biochem Biophys       Date:  2008 Mar-Apr       Impact factor: 0.834

9.  The gut microbiome as a target for regulatory T cell-based immunotherapy: induction of regulatory lymphocytes by oral administration of anti-LPS enriched colostrum alleviates immune mediated colitis.

Authors:  Ami Ben Ya'acov; Yoav Lichtenstein; Lidya Zolotarov; Yaron Ilan
Journal:  BMC Gastroenterol       Date:  2015-10-30       Impact factor: 3.067

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.